…on the latest industry updates. As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines are once again making the headlines, but in the last week we have…
News round-up for 18-22 September by DDW Digital Content Editor Diana Spencer. As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines are once again making the headlines,…
…Products (ATMP) and Vaccines Network’ specifically targets researchers in the north of the UK and will coordinate events, talks from industry leaders and networking opportunities for the advanced therapies industry….
…Nipah virus is fatal in up to 75% of cases and survivors can be left with long-term neurological complications. There are currently no approved vaccines or treatments for Nipah virus…
…its efficacy against existing vaccines. This trial is part of Project NextGen, which coordinates across the US government and the private sector to advance innovative vaccines and therapeutics into clinical…
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has announced data from a pre-defined interim analysis related to the lung cohort…
…vaccines. The strategic R&D collaboration focuses on three pillars: Applying Moderna’s mRNA technology for in vivo expression of Immatics’ next-generation, half-life extended TCR bispecifics (TCER), targeting cancer-specific HLA-presented peptides. Enabling…
…Administration. “As Covid-19 is expected to adopt a seasonal pattern, similar to other respiratory viruses, we remain committed to providing Covid-19 vaccines that are better matched to relevant circulating variants…
…UK innovation and research depends on international collaborations which are crucial for driving advancements in all areas of science, including the discovery and early development of new medicines and vaccines.”…
…using technology to identify previously undruggable targets has enabled the development of therapeutics and vaccines. The disease areas that have particularly benefitted from new processes, innovation and technology and the…
…the sector produced effective medicines and vaccines, and employed highly skilled staff, up from 69% last year, demonstrating the value it brings to society. However, concerns were expressed over limitations…
…Phase I clinical trial of VENT-02, an oral, brain-penetrant NLRP3 inhibitor from Ventus Therapeutics, has launched with the dosing of the first patient. Routine vaccines as effective as antibodies against…
…25%, 27%, and 35%. Enhancing the efficiency of immune cells “We hypothesise that the reduced risk of AD associated with vaccines is likely due to a combination of mechanisms,” another…
It is believed that new Covid-19 vaccines developed by Pfizer/BioNTech, Moderna and Novavax will be effective against the fast-spreading EG.5 strain. EG.5 or ‘Eris’ has been found in more than…
…Chemistry at New York University (NYU) and the study’s senior author. Viruses have different proteins on their surfaces that are often the targets of therapeutics like monoclonal antibodies and vaccines….
